OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Musculoskeletal Disease is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge	91
Pathophysiology of musculoskeletal pain: a narrative review	62
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis	51
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of	43
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review	42
Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways	42
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders	34
Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation	31
Comparative effectiveness of treatment options for subacromial shoulder conditions: a systematic review and network meta-analysis	29
A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening	29
Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis	27
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)	27
Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review	26
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders	26
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies	26
Body composition in patients with rheumatoid arthritis: a narrative literature review	26
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis	25
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?	23
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus	22
A broad look into the future of rheumatoid arthritis	21
Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study	20
Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis	20
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents	19
Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?	19
Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibito	19

The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients	19
Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study	18
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis	18
Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis	17
Cell-based therapies for rheumatoid arthritis: opportunities and challenges	17
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis	17
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?	17
Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis	16
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort	16
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review	16
Prognostic factors for 1-year functional outcome, quality of life, care demands, and mortality after surgery in Taiwanese geriatric patients with a hip fracture: a prospective cohort study	16
Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review	16
A glance into the future of gout	15
Back pain treatment: a new perspective	15
A glimpse into the future of systemic lupus erythematosus	15
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study	14
Health disparities in rheumatoid arthritis	14
Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review	14
Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis	14
Ten-year survival analysis of patients with primary Sjögren’s syndrome in China: a national prospective cohort study	14
Real-world evidence to assess the effectiveness of platelet-rich plasma in the treatment of knee degenerative pathology: a prospective observational study	14
Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study	13
Association between bone trace elements and osteoporosis in older adults: a cross-sectional study	13
Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials	12
Sjögren syndrome: looking forward to the future	12
Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs	12
Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand	12
The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities	12
Soluble biological markers in osteoarthritis	12
Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence	12
Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group	12
Looking ahead: giant-cell arteritis in 10 years time	12
Latest insights in disease-modifying osteoarthritis drugs development	12
Future challenges in rheumatology – is telemedicine the solution?	11
Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis	11
New insights on multigenic autoinflammatory diseases	11
Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study	11
Mesenchymal stromal cell products for intra-articular knee injections for conservative management of osteoarthritis	11
Stromal vascular fraction therapy for knee osteoarthritis: a systematic review	11
Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis	11
Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all	11
Digital health interventions for osteoporosis and post-fragility fracture care	11
Osteopathic medicine for fibromyalgia: a sham-controlled randomized clinical trial	11
Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases	11
Interstitial lung disease pathology in systemic sclerosis	11
The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials	10
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence	10
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids	10
Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case–control study	10
Bone fragility during the COVID-19 pandemic: the role of macro- and micronutrients	10

A glance into the future of diagnosis and treatment of spondyloarthritis	10
Osteosarcopenia and Long-COVID: a dangerous combination	10
Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy	10
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes	10
Epidemiology and risk of invasive fungal infections in systemic lupus erythematosus: a nationwide population-based cohort study	10
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease	9
The importance of maternal pregnancy vitamin D for offspring bone health: learnings from the MAVIDOS trial	9
Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, case-control study	9
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients	9
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib	9
Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis	9
Age-stratified trends in the progression of spinal radiographic damage in patients with ankylosing spondylitis: a longitudinal study	9
Association of anti-thyroid antibodies with radiographic knee osteoarthritis and chondrocalcinosis: a NHANES III study	9
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study	9
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis	9
Latest advancements in imaging techniques in OA	9
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review	9
Is there still a place for methotrexate in severe psoriatic arthritis?	8
The sonographic identification of cortical bone interruptions in rheumatoid arthritis: a morphological approach	8
The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials	8
A comparison of clinical examination and ultrasound enthesitis indices in patients with psoriatic arthritis, adjusted for concomitant fibromyalgia	8
RETRACTED: Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma	8
Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease	8
A pilot study on deep learning-based grading of corners of vertebral bodies for assessment of radiographic progression in patients with ankylosing spondylitis	8
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study	8
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice	8
Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis	8
Emerging molecular biomarkers in osteoarthritis pathology	8
Ultrasonography predicts the results of labial salivary gland biopsy in patients with suspected Sjögren’s syndrome: a matrix risk model	8
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study	8
Repurposing haloperidol for the treatment of rheumatoid arthritis: an integrative approach using data mining techniques	7
Sarcopenia and bone health: new acquisitions for a firm liaison	7
Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience	7
Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis	7
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)	7
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment	7
The burden of low back pain in children and adolescents with overweight and obesity: from pathophysiology to prevention and treatment strategies	7
Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial	7
Person-centered versus body-centered approaches in osteopathic care for chronic pain conditions	7
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review	7
Comparison of clinical efficiency between intra-articular injection of platelet-rich plasma and hyaluronic acid for osteoarthritis: a meta-analysis of randomized controlled trials	7
Acute effects of exercise on pain symptoms, clinical inflammatory markers and inflammatory cytokines in people with rheumatoid arthritis: a systematic literature review	7
A theoretical framework to improve the construct for chronic pain disorders using fibromyalgia as an example	7
Nutritional and physical activity issues in frailty syndrome during the COVID-19 pandemic	7
Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults	7
Psoriatic arthritis: prospects for the future	7
Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis	7
Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis	7
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review	7
Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: data from the ASAS-COMOSPA study	6
Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues	6
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials	6
Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity	6
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis	6
Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases	6
Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib	6
Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis	6
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients	6
Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study	6
Predicting osteoarthritis in adults using statistical data mining and machine learning	6
Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey	6
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance	6
Psychological profiles in adults with knee OA-related pain: a replication study	5
Early knee OA definition–what do we know at this stage? An imaging perspective	5
Intervertebral disc therapies for non-specific chronic low back pain: a systematic review and meta-analysis	5
Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study	5
Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol	5
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis	5
Impact of sarcopenia on rehabilitation outcomes after total knee replacement in older adults with knee osteoarthritis	5
The application of machine learning in early diagnosis of osteoarthritis: a narrative review	5
Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study	5
Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system	5
SCORE2 versus SCORE in patients with systemic lupus erythematosus	5
Fracture in clinical studies of tofacitinib in rheumatoid arthritis	5
Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis	5
High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study	5
Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression	5
Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study	5
Rehabilitation of the face and temporomandibular joint in systemic sclerosis	5
Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis	5